On Monday, Voyager Therapeutics (NASDAQ:VYGR) received a Buy rating from Citi, with a price target set at $12.00. Trading at $6.86, the stock has shown strong momentum with a 19.3% gain in the past week. According to InvestingPro data, analysts are highly bullish, with price targets ranging from $11 to $30.
The biotechnology company, which is in the early stages of clinical development, is focusing on creating treatments for neurological disorders. With its proprietary TRACER platform, Voyager has positioned itself as a leader in the CNS gene therapy field and a sought-after business development partner within the pharmaceutical industry. The company maintains a strong financial position with a "GREAT" financial health score according to InvestingPro, holding more cash than debt and maintaining a healthy current ratio of 8.45.
Voyager Therapeutics is anticipated to submit Investigational New Drug (IND) applications for its wholly-owned SOD1 ALS gene therapy and two partnered gene therapies for Friedreich’s ataxia and Parkinson’s disease in 2025. The company is also exploring non-viral CNS delivery methods for a variety of molecules, including oligonucleotides and siRNA, via its receptor-targeted blood-brain barrier transport technology. This could expand the potential applications of Voyager's delivery technology.
The firm's anti-tau antibody, VY7523, is currently undergoing a Phase 1a trial with healthy volunteers, and pharmacokinetic and safety data are expected in the first half of 2025. Additional proof-of-concept Tau-PET imaging data for VY7523 in Alzheimer’s patients are projected to be available in the second half of 2026.
Citi's stance on Voyager Therapeutics reflects optimism about the company's platform capabilities in both clinical and business development terms. The analyst views the company's prospects as high-risk but with significant potential rewards, underlining the innovative nature of Voyager's approach to gene therapy for central nervous system disorders. Based on InvestingPro's Fair Value analysis, the stock appears undervalued, with 8 additional ProTips and comprehensive financial metrics available to subscribers through the Pro Research Report.
In other recent news, Voyager Therapeutics has been making significant strides in the field of neurological disease treatments, as evidenced by their third-quarter 2024 financial report and recent earnings call. The company, which reported $24.6 million in collaboration revenue and $38.4 million in operational expenses, also highlighted a substantial cash reserve of $345.4 million, projected to fund operations into 2027 and support multiple clinical data readouts.
Oppenheimer maintained a positive outlook on Voyager and reiterated an Outperform rating. The firm's analysis was particularly focused on the implications of the Phase 2a TOGETHER study of bepranemab in early Alzheimer's disease for Voyager's anti-tau monoclonal antibody VY7523. The results of this study were seen as a positive indicator for VY7523's potential.
Voyager has completed enrollment for VY7523's single ascending dose trial and plans to report initial data in the first half of 2025. A multiple ascending dose trial for early Alzheimer's patients is set for 2025, with tau PET imaging data expected by the end of 2026. The company's tau silencing gene therapy program is also on track for U.S. IND and Health Canada CTA filing in 2026.
These recent developments reflect Voyager's commitment to developing treatments for neurological diseases, with a robust pipeline of wholly-owned and partnered programs. The company is optimistic about upcoming clinical milestones and partnerships and anticipates initial safety and pharmacokinetic data from VY7523 in healthy volunteers in the first half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.